Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: Results of a randomized trial

Journal of Infectious Diseases

Volumn 197, Issue 10, 2008, Pages 1361-1368

  McClelland, R Scott ^a,b   Richardson, Barbra A ^a   Hassan, Wisal M ^a   Chohan, Vrasha ^b   Lavreys, Ludo ^a,b   Mandaliya, Kishorchandra ^c   Kiarie, James ^b   Jaoko, Walter ^b   Ndinya Achola, Jeckoniah O ^b   Baeten, Jared M ^a   Kurth, Ann E ^a   Holmes, King K ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c Department of Obstetrics and Gynaecology   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; METRONIDAZOLE; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; BACTERIAL COLONIZATION; CANDIDA ALBICANS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DIRECTLY OBSERVED THERAPY; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; KENYA; LACTOBACILLUS; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; PROSTITUTION; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; SKIN TINGLING; STATISTICAL ANALYSIS; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; VAGINA CANDIDIASIS; VAGINA FLORA; VAGINITIS; VOMITING;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; CANDIDIASIS, VULVOVAGINAL; FEMALE; FLUCONAZOLE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; KENYA; LACTOBACILLUS; METRONIDAZOLE; MIDDLE AGED; PLACEBOS; PROSTITUTION; TRICHOMONAS VAGINITIS; VAGINA; VAGINOSIS, BACTERIAL;

EID: 43949097227     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/587490     Document Type: Article

References (37)

1. Joint United Nations Progam on AIDS (UNAIDS)/World Health Organization. AIDS epidemic update: December 2006. Geneva, Switzerland: UNAIDS, 2006:1-50.
2. Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006; 368:489-504.
3. Martin HL Jr, Nyange PM, Richarson BA, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis 1998; 178:1053-9.
4. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 2001; 28:579-97.
5. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180:1863-8.
6. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004; 351:876-83.
7. Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006; 194:1283-9.
8. Martin HL Jr, Jackson DJ, Mandaliya K, et al. Preparation for AIDS vaccine evaluation in Mombasa, Kenya: establishment of seronegative cohorts of commercial sex workers and trucking company employees. AIDS Res Hum Retroviruses 1994; 10(Suppl 2):S235-7.
9. World Health Organization (WHO). Guidelines for the management of sexually transmitted infections. Geneva, Switzerland: WHO, 2003:1-91
10. World Health Organization (WHO), Centers for Disease Control and Prevention. Guidelines for appropriate evaluations of HIV testing technologies in Africa. Harare, Zimbabwe: WHO, 2001:1-48.
11. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29:297-301.
12. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach DA, Holmes KK. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74:14-22.
13. Eschenbach DA, Davick PR, Williams BL, et al. Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol 1989; 27:251-6.
14. George SL, Desu MM. Planning the size and duration of a clinical trial studying the time to some critical event. J Chronic Dis 1974; 27:15-24.
15. Taha TE, Kumwenda NI, Kafulafula G, et al. Intermittent intravaginal antibiotic treatment of bacterial vaginosis in HIV-uninfected and -infected women: a randomized clinical trial. PLoS Clin Trials 2007; 2:e10.
16. Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992; 14(Suppl 1):S148-53.
17. Hillier SL, Lipinski C, Briselden AM, Eschenbach DA. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis. Obstet Gynecol 1993; 81:963-7.
18. Livengood CH 3rd, Soper DE, Sheehan KL, et al. Comparison of oncedaily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis. Sex Transm Dis 1999; 26:137-42.
19. Lyng J, Christensen J. A double-blind study of the value of treatment with a single dose tinidazole of partners to females with trichomoniasis. Acta Obstet Gynecol Scand 1981; 60:199-201.
20. Wawer MJ, Sewankambo NK, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Lancet 1999; 353:525-35.
21. McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007; 195:698-702.
22. Blackwell AL, Fox AR, Phillips I, Barlow D. Anaerobic vaginosis (non-specific vaginitis): clinical, microbiological, and therapeutic findings. Lancet 1983; 2:1379-82.
23. Eschenbach DA, Critchlow CW, Watkins H, et al. A dose-duration study of metronidazole for the treatment of nonspecific vaginosis. Scand J Infect Dis Suppl 1983; 40:73-80.
24. Jones BM, Geary I, Alawattegama AB, Kinghorn GR, Duerden BI. In-vitro and in-vivo activity of metronidazole against Gardnerella vaginalis, Bacteroides spp. and Mobiluncus spp. in bacterial vaginosis. J Antimicrob Chemother 1985; 16:189-97.
25. Swedberg J, Steiner JF, Deiss F, Steiner S, Driggers DA. Comparison of single-dose vs one-week course of metronidazole for symptomatic bacterial vaginosis. JAMA 1985; 254:1046-9.
26. Hovik P. Nonspecific vaginitis in an outpatient clinic. Scand J Infect Dis Suppl 1983; 40:107.
27. Jerve F, Berdal TB, Bohman P, et al. Metronidazole in the treatment of non-specific vaginitis (NSV). Br J Vener Dis 1984; 60:171-4.
28. Hager WD, Brown ST, Kraus SJ, Kleris GS, Perkins GJ, Henderson M. Metronidazole for vaginal trichomoniasis: seven-day vs single-dose regimens. JAMA 1980; 244:1219-20.
29. Korner B, Jensen HK. Sensitivity of Trichomonas vaginalis to metronidazole, tinidazole, and nifuratel in vitro. Br J Vener Dis 1976; 52:404-8.
30. Dykers JR. Single-dose metronidazole for trichomonal vaginitis: patient and consort. N Engl J Med 1975; 293:23-4.
31. Fleury FJ, Van Bergen WS, Prentice RL, Russell JG, Singleton JA, Standard JV. Single dose of two grams of metronidazole for Trichomonas vaginalis infection. Am J Obstet Gynecol 1977; 128:320-3.
32. Sobel JD, Brooker D, Stein GE, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol 1995; 172:1263-8.
33. Prasertsawat PO, Bourlert A. Comparative study of fluconazole and clotrimazole for the treatment of vulvovaginal candidiasis. Sex Transm Dis 1995; 22:228-30.
34. Mikamo H, Kawazoe K, Sato Y, Hayasaki Y, Tamaya T. Comparative study on the effectiveness of antifungal agents in different regimens against vaginal candidiasis. Chemotherapy 1998; 44:364-8.
35. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360:971-7.
36. Kaul R, Kimani J, Nagelkerke NJ, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004; 291:2555-62.
37. Myer L, Denny L, Telerant R, Souza M, Wright TC Jr, Kuhn L. Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis 2005; 192:1372-80.